Table of Contents The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies. Nippon India Pharma Fund is a Equity - Sectoral fund launched on 5 Jun 04. It is a fund with High risk and has given a Below is the key information for Nippon India Pharma Fund Returns up to 1 year are on Historical performance (Yearly) on absolute basis Nippon India PHARMA Fund - G
Scheme Objective
CAGR
return of 20.6% since its launch. Ranked 35 in Sectoral
category. Return for 2024 was 34% , 2023 was 39.2% and 2022 was -9.9% . NAV as on 21 Jul 25 ₹522.364 ↓ -0.57 (-0.11 %) Net Assets (AUM) as on 30 Jun 2025 ₹8,569 Cr. Launch Date 5 Jun 2004 Category Equity - Sectoral Rating ☆☆ Type Open Ended Fund Risk High AMC Nippon Life Asset Management Ltd. Alpha Ratio -2.16 Expense Ratio 1.88 % Sharpe Ratio 0.566 Information Ratio -0.55 Benchmark Not Available Min Investment ₹5,000 Min SIP Investment ₹100 Exit Load 0-1 Years (1%),1 Years and above(NIL) NAV Price Chart
Returns
Annual Compounded Returns
absolute basis
& more than 1 year are on CAGR (Compound Annual Growth Rate)
basis. as on 21 Jul 25 Duration Returns 1 Month 3.3% 3 Month 7.3% 6 Month 4.9% 1 Year 12.3% 3 Year 24.2% 5 Year 21.4% 10 Year 15 Year Since launch 20.6% Historical Annual Returns
Year Returns 2024 34% 2023 39.2% 2022 -9.9% 2021 23.9% 2020 66.4% 2019 1.7% 2018 3.6% 2017 7.6% 2016 -10.6% Growth of 10k Over Years
Date Value 30 Jun 20 ₹10,000 30 Jun 21 ₹16,184 30 Jun 22 ₹13,821 30 Jun 23 ₹16,792 30 Jun 24 ₹23,641 30 Jun 25 ₹27,501 Asset Allocation
Asset Class Value Cash 1.42% Equity 98.58% Sector Allocation
Sector Value Health Care 98.58% Top Securities Holdings / Portfolio
Holdings/Securities
Name Global Industry Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 09 | SUNPHARMADrug Manufacturers - Specialty & Generic 13% ₹1,050 Cr 6,256,349 Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLABDrug Manufacturers - Specialty & Generic 9% ₹793 Cr 1,198,808
↓ -100,000 Lupin Ltd (Healthcare)
Equity, Since 31 Aug 08 | LUPINDrug Manufacturers - Specialty & Generic 6% ₹486 Cr 2,483,991 Cipla Ltd (Healthcare)
Equity, Since 31 May 08 | CIPLADrug Manufacturers - Specialty & Generic 6% ₹469 Cr 3,200,000 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 30 Jun 11 | DRREDDYDrug Manufacturers - Specialty & Generic 5% ₹458 Cr 3,662,170 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Sep 20 | APOLLOHOSPMedical Care Facilities 5% ₹446 Cr 648,795 Medplus Health Services Ltd (Healthcare)
Equity, Since 30 Nov 22 | 543427Pharmaceutical Retailers 4% ₹351 Cr 3,627,277 GlaxoSmithKline Pharmaceuticals Ltd (Healthcare)
Equity, Since 31 Aug 22 | GLAXODrug Manufacturers - General 4% ₹311 Cr 943,731
↓ -68,190 Vijaya Diagnostic Centre Ltd (Healthcare)
Equity, Since 30 Sep 21 | 543350Diagnostics & Research 3% ₹271 Cr 2,831,564 Narayana Hrudayalaya Ltd (Healthcare)
Equity, Since 30 Jun 17 | NHMedical Care Facilities 3% ₹245 Cr 1,406,946
↓ -19,224
Talk to our investment specialistFund Managers
Name Since Tenure Sailesh Raj Bhan 1 Apr 05 20.18 Yr. Kinjal Desai 25 May 18 7.02 Yr. Custodians
Company Address Deutsche Bank AG Deutsche Bank AG,Kodak House, 22, D.N. Road, Registrar & Transfer Agent
KFin Technologies Ltd Address 138 -Suyesh Solitaire, Nr. Podar International School,Kudasan, Gandhinagar, Gujarat FAX N.A Email N.A Administrator Companies
Company Address Nippon India Mutual Fund 9th Floor, Crescenzo, C-38 & 39,,G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400051 Auditors
Company Address Haribhakti & Co. Chartered Accountants 42, Free Press House,4th Floor,,215, Nariman Point, All Plan & Options
Fund and Plan NAV 6 Month 1 Year 3 Year 5 Year Nippon India Pharma Fund
Normal Dividend, Payout ₹121.75
↓ -0.13 4.06 % 11.35 % 23.55 % 23.97 % Nippon India Pharma Fund
Normal Dividend, Reinvestment ₹121.75
↓ -0.13 4.06 % 11.35 % 23.55 % 23.97 % Nippon India Pharma Fund
Growth ₹522.364
↓ -0.57 4.92 % 12.28 % 24.2 % 21.45 % Data as on 21 Jul 25